| 000 | 01640 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513033209.0 | ||
| 264 | 0 | _c19951205 | |
| 008 | 199512s 0 0 eng d | ||
| 022 | _a0732-8893 | ||
| 024 | 7 |
_a10.1016/0732-8893(95)00102-g _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBurke, J P | |
| 245 | 0 | 0 |
_aA retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital. _h[electronic resource] |
| 260 |
_bDiagnostic microbiology and infectious disease _c |
||
| 300 |
_a167-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBacterial Infections _xdrug therapy |
| 650 | 0 | 4 |
_aCefotaxime _xadministration & dosage |
| 650 | 0 | 4 |
_aCephalosporins _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLength of Stay |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aPestotnik, S L | |
| 700 | 1 | _aClassen, D C | |
| 700 | 1 | _aLloyd, J F | |
| 773 | 0 |
_tDiagnostic microbiology and infectious disease _gvol. 22 _gno. 1-2 _gp. 167-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0732-8893(95)00102-g _zAvailable from publisher's website |
| 999 |
_c7586471 _d7586471 |
||